脑苷肌肽注射液治疗脑出血的循证药物经济学评价  

Evidence-based pharmacoeconomics evaluation of Cattle Encephalon Glycoside and Ignotin Injection on cerebral hemorrhage

作　　者：王凯[1,2] 杨珍珍 王淑梅 田夏[2] 郑丽英 韩晟[2] WANG Kai;YANG Zhen-zhen;WANG Shu-mei;TIAN Xia;ZHENG Li-ying;HAN Sheng

机构地区：[1]河北医科大学第二医院,河北石家庄050000 [2]北京大学医药管理国际研究中心,北京100191

出　　处：《中国药物经济学》2018年第5期5-11,共7页China Journal of Pharmaceutical Economics

摘　　要：目的评估脑苷肌肽注射液治疗脑出血的临床效果及经济性;方法计算机检索Pubmed/medline、Cochrane Library、中国期刊全文数据库、中文期刊全文数据库和万方数据知识服务平台,收集脑苷肌肽注射液治疗脑出血的随机对照试验,对纳入的文献进行质量评价,使用Rev Man 5.3软件对脑苷肌肽注射液临床疗效进行Meta分析,使用成本-效果分析方法对其进行经济性评价。结果共纳入4篇文献,共计431例患者。Meta分析结果显示,脑苷肌肽注射液联合常规治疗的有效率与单纯常规治疗之间差异有统计学意义[RR=1.15,95%CI(1.06,1.25),P<0.001],在常规治疗基础上使用脑苷肌肽注射液能提高脑出血患者的临床有效率。成本-效果分析显示,与单纯常规治疗相比,在常规治疗基础上使用脑苷肌肽注射液平均每人每天需要额外支付302.50元,14 d额外支付4228.70元,ICER为363.29元/%,即有效率增加一个百分比平均每人需要多花363.29元。结论常规治疗基础上使用脑苷肌肽注射液在效果增加的同时,成本也会增加,支付者需基于对相关指标的支付意愿进行决策。Objective to evaluate the effectiveness and economics of Cattle Encephalon Glycoside and Ignotin Injection on cerebral hemorrhage.Methods Randomized controlled trials（RCTs） were collected by searching Pubmed/medline,Cochrane Library,CNKI,VIP and Wan Fang database.Meta-analysis was conduct by Rev Man 5.3 software to access the clinical effect of cattle encephalon clycoside and ignotin injection on cerebral hemorrhage; cost-effectiveness analysis was used to evaluate economics of cattle encephalon glycoside and ignotin injection. Results 4 RCTs were included,involving 431 patients.System evaluation results show that,compared with the conventional treatment group,the effective rate of conventional treatment combined with cattle encephalon glycoside and ignotin injection were significantly higher（P〈0.001）.cost-effectiveness analysis showed that each patient need to pay an extra 302.5 yuan per day and 4228.70 yuan in 14 days. The ICER were 363.29 yuan/%.Conclusion On the treatment of cerebral hemorrhage,cattle encephalon glycoside and ignotin injection were considered to improve the outcome,along with rising costs.

关 键 词：脑苷肌肽注射液 Meta分析 有效率 成本效果 经济学评价 

分 类 号：R743.34[医药卫生—神经病学与精神病学]